Halozyme price target raised to $96 from $94 at Morgan Stanley

Morgan Stanley yesterday raised the firm’s price target on Halozyme (HALO) to $96 from $94 and keeps an Overweight rating on the shares. The firm adjusted the target as part of a Q1 preview for the smaller cap biotechnology group. Halozyme’s royalty revenue growth continues to be driven by strong underlying demand for Enhanze, the analyst tells investors in a research note.